NBTX

NanobiotixD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$32.30

-12.1% vs current

Most likely

Base case

55%

Probability

Target price

$21.53

-41.4% vs current

B-

Bear case

20%

Probability

Target price

$8.61

-76.6% vs current

AI sentiment snapshot

Latest data as of 2026-01-16

AI commentary

Market sentiment is mixed: third-party targets show high dispersion, producing headline-driven volatility. Commentary centers on binary clinical/regulatory outcomes with wide near-term estimate divergence [#SERP-1][#SERP-2][#SERP-3].

RankAlpha Sentiment AI - 2026-01-16

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-16catalystAnalyst updates / consensus revisionsHigh impact

Wide published target dispersion may trigger analyst revisions and headline volatility; used published ranges as a sanity check [#SERP-1][#SERP-2].

2027-01-16eventPivotal clinical readout for lead radiotherapy asset (estimated)High impact

No firm public date disclosed; conservatively estimated within 12 months. A binary clinical outcome could drive a material re-rating [#SERP-3].

2027-01-16catalystRegulatory / commercialization milestonesHigh impact

Regulatory filing/approval or early commercialization would be value-accretive but is low probability within 12 months absent positive clinical data [#SERP-2][#SERP-4].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-16 • Updated nightlySource: Internal modelMethodology